Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

VolitionRx hails 'best yet' in early colorectal cancer detection

In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas
VolitionRx hails 'best yet' in early colorectal cancer detection
The trial was double blinded and age-adjusted with the results at 78% specificity
VolitionRx (NYSE:VNRX) has published another set of strong trial results for NuQ, its blood test for cancer.
 
In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas, or pre-cancerous polyps, that were most likely to become cancerous.
 
A panel of five of NuQ biomarker assays also detected 86% of early colorectal cancers.
 
Hvidore University carried out the study to assess how effective was NuQ in detecting adenomas before they become cancerous.
 
The trial was double blinded and age-adjusted with the results at 78% specificity.
 
NuQ uses biomarker assays that can identify fragments of chromosomes, called nucleosomes, circulating in the blood and analyse them for epigenetic modifications that signal that cancer is present. The assays  require only a single drop of blood from patients, Volition added.
 
Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital said: "This study shows extremely good detection of dangerous pre-cancer and early-stage cancer with the non-invasive NuQ blood test.”
 
We are now working with VolitionRx on large retrospective and prospective trials in both screening and symptomatic populations.
 
Cameron Reynolds, VolitionRx’s chief executive, said: "Not only do these results demonstrate our best detection rates to date for colorectal adenomas, but they further confirm the progress that VolitionRx is making in identifying new NuQ biomarker assays and optimizing panels to produce the most accurate detection rates of adenomas and colorectal cancers.”
 
Talking to Proactive, he added: "Just about every other biomarker out there detects late stage cancer much better than early stage purely because you have a lot more of the marker.
 
"So to have 86% of stage 1 cancers and 75% of pre-cancers is far better than we could have hoped for."
 
He noted particularly that the results of the adenomas, or pre-cancerous polyps were far better than the firm could have hoped for.
 
A commercial product for clinical use in detecting colorectal cancer is expected to be launched later this year.
PhilW.jpg
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile

VolitionRx Timeline

Related Articles

Magnified view of cancer cells
April 19 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
nanobiotix_good_-_gg_569cea9f8006c.png
January 18 2016
Investors in pioneering cancer firm (EPA:NANO) can look forward to a data-rich 2016...

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.